R Squared’s Adaptive Biotechnologies ADPT Stock Holding History

R Squared’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-890	Closed	-$5.34K	–	309
2024 Q4	$5.34K	Buy	+890	New	+$4.91K	0.01%	1303

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

R Squared's ADPT Position: Q1 2025 in Review

R Squared sold out of Adaptive Biotechnologies (ADPT) in Q1 2025, closing a stake of 890 shares — an estimated $5.34K sold.

R Squared first reported a position in ADPT in Q4 2024 and held it in 1 quarter. The position peaked at $5.34K in Q4 2024. 225 funds tracked by Wall St. Rank hold ADPT as of Q1 2025.

R Squared reported no remaining Adaptive Biotechnologies position as of Q1 2025 after selling out during the quarter.
R Squared sold 890 Adaptive Biotechnologies shares in Q1 2025, an estimated $5.34K.
R Squared first reported a position in Adaptive Biotechnologies in Q4 2024 and held it in 1 quarter.
R Squared's Adaptive Biotechnologies position peaked at $5.34K in Q4 2024.
225 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.